FI933193A - Behandling av neoplastisk sjukdom med interleukin-10 - Google Patents

Behandling av neoplastisk sjukdom med interleukin-10 Download PDF

Info

Publication number
FI933193A
FI933193A FI933193A FI933193A FI933193A FI 933193 A FI933193 A FI 933193A FI 933193 A FI933193 A FI 933193A FI 933193 A FI933193 A FI 933193A FI 933193 A FI933193 A FI 933193A
Authority
FI
Finland
Prior art keywords
interleukin
sjukdom
neoplastisk
behandling
med
Prior art date
Application number
FI933193A
Other languages
English (en)
Other versions
FI933193A0 (fi
Inventor
Paulo J M Vieira
Kevin W Moore
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI933193A0 publication Critical patent/FI933193A0/fi
Publication of FI933193A publication Critical patent/FI933193A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5428IL-10
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2066IL-10
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16211Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
FI933193A 1991-01-16 1993-07-14 Behandling av neoplastisk sjukdom med interleukin-10 FI933193A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64134791A 1991-01-16 1991-01-16
PCT/US1992/000066 WO1992012725A1 (en) 1991-01-16 1992-01-15 Treatment of neoplastic disease with interleukin-10

Publications (2)

Publication Number Publication Date
FI933193A0 FI933193A0 (fi) 1993-07-14
FI933193A true FI933193A (fi) 1993-07-14

Family

ID=24571976

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933193A FI933193A (fi) 1991-01-16 1993-07-14 Behandling av neoplastisk sjukdom med interleukin-10

Country Status (18)

Country Link
EP (1) EP0567576B1 (fi)
JP (1) JP3260368B2 (fi)
KR (1) KR100207766B1 (fi)
AT (1) ATE116550T1 (fi)
AU (1) AU652030B2 (fi)
CA (1) CA2100553A1 (fi)
CZ (1) CZ282523B6 (fi)
DE (1) DE69201128T2 (fi)
DK (1) DK0567576T3 (fi)
ES (1) ES2068705T3 (fi)
FI (1) FI933193A (fi)
GR (1) GR3015510T3 (fi)
HK (1) HK192196A (fi)
HU (1) HU218598B (fi)
NO (1) NO310444B1 (fi)
OA (1) OA09908A (fi)
SK (1) SK279556B6 (fi)
WO (1) WO1992012725A1 (fi)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106823A (en) 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
JP3494647B2 (ja) * 1992-08-20 2004-02-09 シェリング・コーポレーション Il−4および/またはil−10ならびにそれらに対する抗体の新規な用途
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
AU707019B2 (en) * 1994-01-20 1999-07-01 Schering Corporation Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
EP1621206A1 (en) 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
AU5827000A (en) * 1999-07-16 2001-02-05 Maria Teresa Bejarano Viral il-10 uses
EP1324779B1 (en) 2000-09-29 2011-07-20 Schering Corporation Pegylated interleukin-10
CA2664304C (en) 2006-09-28 2017-08-22 Schering Corporation Use of pegylated il-10 to treat cancer
PL2379115T3 (pl) 2008-12-17 2018-03-30 Merck Sharp & Dohme Corp. Wytwarzanie i zastosowania mono- i di-peg il-10
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
JP6509867B2 (ja) 2013-08-30 2019-05-08 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためにインターロイキン−10を使用する方法
ES2862139T3 (es) 2013-11-11 2021-10-07 Armo Biosciences Inc Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
JP2017536098A (ja) 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−15組成物及びその使用
KR20170084033A (ko) 2014-10-22 2017-07-19 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
CZ283049B6 (cs) * 1989-12-20 1997-12-17 Schering Corporation Protein BCRF1 viru Epstein-Barr schopný inhibovat syntézu gama-interferonu, expresní vekter pro jeho syntézu a farmaceutický přípravek jej obsahující

Also Published As

Publication number Publication date
HU218598B (hu) 2000-10-28
WO1992012725A1 (en) 1992-08-06
NO932570D0 (no) 1993-07-15
FI933193A0 (fi) 1993-07-14
OA09908A (en) 1994-09-15
GR3015510T3 (en) 1995-06-30
KR100207766B1 (ko) 1999-07-15
NO932570L (no) 1993-07-15
AU1261792A (en) 1992-08-27
CZ282523B6 (cs) 1997-07-16
HU9302066D0 (en) 1993-11-29
NO310444B1 (no) 2001-07-09
HUT69962A (en) 1995-09-28
EP0567576A1 (en) 1993-11-03
DE69201128D1 (de) 1995-02-16
AU652030B2 (en) 1994-08-11
DK0567576T3 (da) 1995-06-12
CZ141293A3 (en) 1994-01-19
DE69201128T2 (de) 1995-05-24
HK192196A (en) 1996-10-25
CA2100553A1 (en) 1992-07-17
ATE116550T1 (de) 1995-01-15
JPH06504785A (ja) 1994-06-02
ES2068705T3 (es) 1995-04-16
SK74793A3 (en) 1995-03-08
SK279556B6 (sk) 1998-12-02
JP3260368B2 (ja) 2002-02-25
EP0567576B1 (en) 1995-01-04

Similar Documents

Publication Publication Date Title
FI933193A (fi) Behandling av neoplastisk sjukdom med interleukin-10
KR930702026A (ko) 자기항원의 경구 투여에 의한 자기면역 질병의 치료
AU7044894A (en) (phospho)lipids for combatting hepatitis b virus infection
NO914352L (no) Fremgangsmaate for behandling av brukte katodebunner
IL83775A0 (en) Fumaramide derivatives and pharmaceutical compositions containing them for treating skin diseases
HU891056D0 (en) Process for treating the diseases of the gullet and the stomach-intestine system
MY104521A (en) Treatment of depression.
ES2052670T3 (es) Utilizacion de derivados de 2-pirimidinil-1-piperazina.
ES2117008T3 (es) Metodo de tratamiento con amperozida de la esquizofrenia resistente a la terapia.
IT1222182B (it) Macchina per il trattamento terapeutico di lombalgie e lombosciatalgie
NO173145C (no) Fremgangsmaate for behandling av voerter
SE8306384D0 (sv) Farmaceutisk komposition
SE9000658D0 (sv) Mittel zur behandlung der schlaf-apnoe
NO923541D0 (no) Innretning for medisinsk behandling av kroppsdeler
DE3786442D1 (de) Verwendung von follikelreifungshormon zur herstellung eines therapeutischen mittels zur behandlung von neoplasmen von gonadalem ursprung.
NO171565C (no) Fremgangsmaate for behandling av manganslam
BG31970A1 (en) Operative method for medical treating of chronic lympheden of limb
SE8902106D0 (sv) Anordning foer behandling av ryggpatienter
RO94514A2 (ro) Procedeu pentru tratarea namolurilor
NO920694L (no) Fremgangsmaate for etterbehandling av tremasse
BG33452A1 (en) Means for medical treating of intestine infection
NO170493C (no) Fremgangsmaate for hydrogenerende behandling av klorholdige forbindelser
EP0266114A3 (en) Etodolac for inhibition of joint ankylosis